Published in Atherosclerosis on March 01, 2002
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest (2004) 3.63
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 2.36
Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest (2004) 1.66
Using advanced intercross lines for high-resolution mapping of HDL cholesterol quantitative trait loci. Genome Res (2003) 1.66
Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest (2005) 1.62
Particulate matter and atherosclerosis: role of particle size, composition and oxidative stress. Part Fibre Toxicol (2009) 1.55
High-density lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol (2011) 1.50
Low serum high density lipoprotein cholesterol concentration is an independent predictor for enhanced inflammation and endothelial activation. PLoS One (2015) 1.42
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res (2010) 1.36
Novel biological functions of high-density lipoprotein cholesterol. Circ Res (2012) 1.19
Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. Curr Opin Lipidol (2009) 1.18
Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther (2008) 1.08
The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol (2010) 1.03
Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res (2008) 1.00
Improvement of lipid profile and antioxidant of hypercholesterolemic albino rats by polysaccharides extracted from the green alga Ulva lactuca Linnaeus. Saudi J Biol Sci (2011) 0.97
Regulation of signal transduction by HDL. J Lipid Res (2013) 0.97
Levels of high-density lipoprotein cholesterol (HDL-C) among children with steady-state sickle cell disease. Lipids Health Dis (2010) 0.95
Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. J Chiropr Med (2008) 0.94
Hypolipidemic and antioxidant effects of dandelion (Taraxacum officinale) root and leaf on cholesterol-fed rabbits. Int J Mol Sci (2010) 0.92
Lipid-lowering effects of methanolic extract of Vernonia amygdalina leaves in rats fed on high cholesterol diet. Vasc Health Risk Manag (2008) 0.91
Antidiabetic effect of hydroalcholic urticadioica leaf extract in male rats with fructose-induced insulin resistance. Iran J Med Sci (2012) 0.90
Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein. World J Biol Chem (2010) 0.88
Shorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients. J Biomed Sci (2010) 0.88
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Endothelial lipase-modified high-density lipoprotein exhibits diminished ability to mediate SR-BI (scavenger receptor B type I)-dependent free-cholesterol efflux. Biochem J (2004) 0.87
Serum zinc and magnesium concentrations in type 2 diabetes mellitus with periodontitis. J Indian Soc Periodontol (2014) 0.86
HDL in sepsis - risk factor and therapeutic approach. Front Pharmacol (2015) 0.85
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Vasc Health Risk Manag (2010) 0.85
Cardiovascular risk factors in portuguese obese children and adolescents: impact of small reductions in body mass index imposed by lifestyle modifications. Open Biochem J (2012) 0.85
High density lipoprotein mediated lipid efflux from retinal pigment epithelial cells in culture. Br J Ophthalmol (2006) 0.84
Correlation between high density lipoprotein-cholesterol and remodeling index in patients with coronary artery disease: IDEAS (IVUS diagnostic evaluation of atherosclerosis in Singapore)-HDL study. Int J Cardiovasc Imaging (2011) 0.83
High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT (2012) 0.82
The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver. J Biol Chem (2012) 0.82
Vitamin C may have similar beneficial effects to Gemfibrozil on serum high-density lipoprotein-cholesterol in type 2 diabetic patients. J Res Pharm Pract (2014) 0.81
Effect of vitamin e and selenium supplement on paraoxonase-1 activity, oxidized low density lipoprotein and antioxidant defense in diabetic rats. Bioimpacts (2011) 0.81
Hypocholesterolemic and Antiatherosclerotic Potential of Basella alba Leaf Extract in Hypercholesterolemia-Induced Rabbits. Evid Based Complement Alternat Med (2015) 0.81
Assessment of endothelial dysfunction in childhood obesity and clinical use. Oxid Med Cell Longev (2013) 0.81
Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry. Biochemistry (2014) 0.80
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol (2017) 0.79
Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl. Arch Biochem Biophys (2009) 0.79
High level of serum cholesteryl ester transfer protein in active hepatitis C virus infection. World J Hepatol (2016) 0.78
Native high density lipoproteins (HDL) interfere with platelet activation induced by oxidized low density lipoproteins (OxLDL). Int J Mol Sci (2013) 0.78
Klotho locus, metabolic traits, and serum hemoglobin in hospitalized older patients: a genetic association analysis. Age (Dordr) (2011) 0.78
Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud (2013) 0.77
Location of PRODAN in lipid layer of HDL particle: a Raman study. Eur Biophys J (2008) 0.77
Weight loss is not mandatory for exercise-induced effects on health indices in females with metabolic syndrome. Biol Sport (2015) 0.77
HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease. Clin Biochem Rev (2004) 0.77
The rationality of the hypolipidemic effect of alismatis rhizoma decoction, a classical chinese medicine formula in high-fat diet-induced hyperlipidemic mice. Iran J Pharm Res (2014) 0.77
Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without Diabetes. Int J Endocrinol (2014) 0.77
ATP Synthase β-Chain Overexpression in SR-BI Knockout Mice Increases HDL Uptake and Reduces Plasma HDL Level. Int J Endocrinol (2014) 0.77
Differential regulation of ABCA1 and macrophage cholesterol efflux by elaidic and oleic acids. Lipids (2013) 0.77
Cumulative Hypoxemia During Sleep Predicts Vascular Endothelial Dysfunction in Patients With Sleep-Disordered Breathing. Am J Hypertens (2015) 0.76
Effect of Erythrina variegata seed extract on hyperlipidemia elicited by high-fat diet in wistar rats. J Pharm Bioallied Sci (2010) 0.76
Association of classical markers and establishment of the dyslipidemic sub-phenotype of sickle cell anemia. Lipids Health Dis (2017) 0.75
Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients. Arch Med Sci (2016) 0.75
Postprandial decrease in LDL-cholesterol in men with metabolic syndrome. Open Med (Wars) (2015) 0.75
Increased serum triglyceride clearance and elevated high-density lipoprotein 2 and 3 cholesterol during treatment of primary hypertriglyceridemia with bezafibrate. Curr Ther Res Clin Exp (2003) 0.75
Low HDL levels in sepsis versus trauma patients in intensive care unit. Ann Intensive Care (2017) 0.75
Effects of Cyclo-His-Pro-enriched yeast hydrolysate on blood glucose levels and lipid metabolism in obese diabetic ob/ob mice. Nutr Res Pract (2015) 0.75
Effect of polysaccharide from Bacillus subtilis sp. on cardiovascular diseases and atherogenic indices in diabetic rats. BMC Complement Altern Med (2016) 0.75
S1P in HDL Promotes Interaction Between SR-BI and S1PR1 and Activates S1PR1-Mediated Biological Functions: Calcium Flux and S1PR1 Internalization. J Lipid Res (2016) 0.75
Protection from Cardiovascular Disease Due to Increased High-Density Lipoprotein Cholesterol in African Black Populations: Myth or Reality? Ethn Dis (2016) 0.75
The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications. Coron Artery Dis (2016) 0.75
Low High-Density Lipoprotein and Risk of Myocardial Infarction. Clin Med Insights Cardiol (2015) 0.75
Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection. Front Physiol (2017) 0.75
Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. Int J Nanomedicine (2017) 0.75
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J (2003) 3.48
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med (2006) 2.77
Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation (2006) 2.76
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation (2006) 2.58
Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks. Int J Epidemiol (2002) 2.48
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 2.36
Androgens and coronary artery disease. Endocr Rev (2003) 2.26
Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study. Lancet (2002) 2.25
Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation (2013) 2.11
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest (2011) 2.08
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem (2010) 1.93
Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res (2003) 1.91
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
High impact running improves learning. Neurobiol Learn Mem (2006) 1.88
Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood (2004) 1.85
Coronary microembolization: from bedside to bench and back to bedside. Circulation (2009) 1.85
Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol (2006) 1.80
Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology (2005) 1.79
Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase. J Biol Chem (2006) 1.79
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
Apolipoprotein A-I but not high-density lipoproteins are internalised by RAW macrophages: roles of ATP-binding cassette transporter A1 and scavenger receptor BI. J Mol Med (Berl) (2007) 1.68
Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol (2011) 1.65
High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int (2012) 1.57
Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation (2004) 1.57
Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J (2010) 1.51
Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol (2006) 1.51
Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res (2010) 1.50
Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol (2011) 1.47
FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2007) 1.46
Cerebral venous thrombosis in children: a multifactorial origin. Circulation (2003) 1.46
Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta (2006) 1.45
Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci (2009) 1.44
Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. J Cardiovasc Electrophysiol (2004) 1.43
Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis (2005) 1.43
PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med (2008) 1.42
The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.41
Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Atherosclerosis (2013) 1.41
Effects of passive smoking on heart rate variability, heart rate and blood pressure: an observational study. Int J Epidemiol (2007) 1.40
The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. J Biol Chem (2009) 1.38
Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation (2005) 1.36
High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res (2014) 1.35
Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis (2006) 1.33
Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res (2009) 1.32
Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J (2007) 1.31
High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol (2004) 1.30
Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS Genet (2006) 1.29
Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology (2009) 1.29
Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis (2003) 1.28
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int (2008) 1.26
Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol (2004) 1.26
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin (2004) 1.25
Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther (2005) 1.25
Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem (2010) 1.24
Is the mammalian serine palmitoyltransferase a high-molecular-mass complex? Biochem J (2007) 1.24
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. J Neurol (2002) 1.23
Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspase-independent mechanism. J Cereb Blood Flow Metab (2002) 1.20
Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol (2010) 1.20
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ Res (2009) 1.20
Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis (2010) 1.20
Response to Conroy et al. SCORE Project. Eur Heart J (2003) 1.20
Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res (2006) 1.19
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res (2005) 1.19
Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res (2005) 1.18
Role of endogenous testosterone concentration in pediatric stroke. Ann Neurol (2009) 1.17
Heart rate variability in an ageing population and its association with lifestyle and cardiovascular risk factors: results of the SAPALDIA study. Europace (2006) 1.16
Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med (2002) 1.16
Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res (2005) 1.14
Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem (2010) 1.13
Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant (2006) 1.13
Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes (2002) 1.13
Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis (2006) 1.12
Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun (2002) 1.12
Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol (2007) 1.11
Premature atrial contractions in the general population: frequency and risk factors. Circulation (2012) 1.11
Differentiated quantification of human bile acids in serum by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.11
Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol (2003) 1.11
HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol (2008) 1.11
Binding, internalization and transport of apolipoprotein A-I by vascular endothelial cells. Biochim Biophys Acta (2006) 1.10
Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int (2011) 1.10
Hemodynamic support by left ventricular assist devices reduces cardiomyocyte DNA content in the failing human heart. Circulation (2010) 1.09
An improved method to determine serine palmitoyltransferase activity. J Lipid Res (2009) 1.09
High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J (2013) 1.09
Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis (2011) 1.08